Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Refixia 2000 IU powder and solvent for solution for injection

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Nonacog beta pegol may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Nonacog beta pegol
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

What Refixia is Refixia contains the active substance nonacog beta pegol. It is a long-acting version of factor IX. Factor IX is a protein naturally found in the blood that helps to stop bleeding. What Refixia is used for Refixia is used to treat and prevent bleeding in all groups of patients with haemophilia B (inborn factor IX deficiency). In patients with haemophilia B, factor IX is missing or does not work properly. Refixia replaces this faulty or missing factor IX and helps blood to form clots at the site of bleeding. 2.

What you need to know before you take it

e Refixia

Do not use Refixia • if you are allergic to the active substance or any of the other ingredients of this medicine (listed in section 6). • if you are allergic to hamster proteins. If you are not sure if either of the above applies to you, talk to your doctor before using this medicine. Warnings and precautions Traceability 1

It is important to keep a record of the batch number of your Refixia. So, every time you get a new package of Refixia, note down the date and the batch number (which is on the packaging after Lot) and keep this information in a safe place. Allergic reactions and development of inhibitors There is a rare risk that you may experience a sudden and severe allergic reaction (e.g. anaphylactic reaction) to Refixia. Stop the injection and contact your doctor or an emergency unit immediately if you have signs of an allergic reaction such as rash, hives, weals, itching of large areas of skin, redness and/or swelling of lips, tongue, face or hands, difficulty in swallowing or breathing, shortness of breath, wheezing, tightness of the chest, pale and cold skin, fast heartbeat, and/or dizziness. Your doctor may need to treat you promptly for these reactions. Your doctor may also carry out a blood test to check if you have developed factor IX inhibitors (neutralising antibodies) against your medicine, as inhibitors may develop together with allergic reactions. If you have such inhibitors, you may have a higher risk of sudden and severe allergic reactions (e.g. anaphylactic reaction) during future treatment with factor IX. Because of the risk of allergic reactions with factor IX, your initial treatment with Refixia should be given in a medical clinic or in the presence of health care professionals where proper medical care for allergic reactions can be provided if needed. Talk to your doctor immediately if your bleeding does not stop as expected or if you have to significantly increase the amount of Refixia you need to stop a bleed. Your doctor will do a blood test to check if you have developed inhibitors (neutralising antibodies) against Refixia. The risk for developing inhibitors is highest in people who have have not been treated with factor IX medicines before, typically small children. Blood clots Tell your doctor, if any of the following apply to you as there is an increased risk of blood clots during treatment with Refixia: • you have recently had surgery • you suffer from other serious illness e.g. liver disease, heart disease, or cancer • you have risk factors for heart disease e.g high blood pressure, obesity, or smoking. Kidney disorder (nephrotic syndrome) There is a rare risk of developing a specific kidney disorder called "nephrotic syndrome" following high doses of factor IX in haemophilia B patients with factor IX inhibitors and a history of allergic reactions. Catheter-related problems If you have a central venous access device (CVAD), you may develop infections or blood clots at the site of the catheter. Other medicines and Refixia Tell your doctor if you are taking, have recently taken or might take any other medicines. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using Refixia. Driving and using machines Refixia has no influence on the ability to drive and use machines. Refixia contains sodium This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially "sodiumfree". In case of treatment with multiple vials, the total sodium content should be taken into consideration. 2

3.

How to use Refixia

Treatment with Refixia will be started by a doctor who is experienced in the care of patients with haemophilia B. Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure about how to use Refixia. Your doctor will calculate the right dose for you. The dose will depend on your weight and what the medicine is being used for. Prevention of bleeding The usual dose of Refixia is 40 international units (IU) per kg of body weight. This is given as one injection every week. Your doctor may choose another dose or change how often the injections should be given, based on your need. Treatment of bleeding The usual dose of Refixia is 40 international units (IU) per kg of body weight. Depending on the location and the severity of bleeding you may need a higher dose (80 IU per kg) or extra injections. Discuss with your doctor the dose and number of injections you need. Use in children and adolescents Refixia can be used in children and adolescents of all ages. The dose in children and adolescents is also calculated according to body weight and is the same dose as for adults.

How to take it

Refixia is available as powder and solvent that is made up into a solution (reconstitution) and given as an injection into a vein. See "Instructions on how to use Refixia" for more information. If you use more Refixia than you should If you use more Refixia than you should, contact your doctor. If you have to significantly increase the amount of Refixia you need to stop a bleed, talk to your doctor immediately. For further information, see section 2 "Allergic reactions and development of inhibitors". If you forget to use Refixia If you forget a dose, inject the missed dose as soon as you remember. Do not inject a double dose to make up for a forgotten dose. If you are in doubt contact your doctor. If you stop using Refixia If you stop using Refixia you may no longer be protected against bleeding or a current bleed may not stop. Do not stop using Refixia without talking to your doctor. If you have any further questions on the use of this medicine, ask your doctor. 4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Allergic reactions are possible with this medicine. If sudden and severe allergic reactions (e.g. anaphylactic reactions) occur, the injection must be stopped immediately. You must contact your doctor or an emergency unit immediately if you have early signs of a severe allergic reaction (anaphylactic reaction) such as: • difficulty in swallowing or breathing • shortness of breath or wheezing • chest tightness 3

• • •

redness and/or swelling of the lips, tongue, face or hands rash, hives, weals or itching pale and cold skin, fast heartbeat, and/or dizziness (low blood pressure).

For children not previously treated with factor IX medicines, inhibitors (see section 2) may form commonly (up to 1 in 10 patients). If this happens, the medicine may stop working properly and your child may experience persistent bleeding. If this happens, you should contact your doctor immediately. The following side effects have been observed with Refixia: Common side effects (may affect up to 1 in 10 people) • allergic reactions (hypersensitivity). This may become severe and could be life-threatening (anaphylactic reactions) • itching (pruritus) • skin reactions at the site of injection • feeling sick (nausea) • feeling very tired. • rash • Children not previously treated with factor IX medicines: neutralising antibodies (inhibitors), anaphylactic reactions. Uncommon side effects (may affect up to 1 in 100 people) • heart palpitations • hot flush. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5.

How to store it

Refixia

Keep this medicine out of the sight and reach of children. Do not use Refixia after the expiry date which is stated after "EXP" on the carton and on the vial and the pre-filled syringe labels. The expiry date refers to the last day of that month. Store in a refrigerator (2 °C – 8 °C). Do not freeze. Keep the vial in the outer carton in order to protect from light. Refixia may be taken out of the refrigerator for a maximum period of 1 year and stored at room temperature (up to 30 °C). Please record on the carton the date Refixia is removed from the refrigerator and placed at room temperature. This new expiry date should never exceed the one initially mentioned on the outer carton. If the medicine has not been used before the new expiry date, it should be disposed of. After storage at room temperature the medicine must not be put back in the refrigerator. Use the injection immediately after making up the solution (reconstitution). If it cannot be used immediately, use within 24 hours if stored in a refrigerator at 2 °C – 8 °C or within 4 hours if stored out of the refrigerator at a maximum temperature of 30 °C.

4

The powder in the vial appears as a white to off-white powder. Do not use the powder if the colour has changed. The reconstituted solution will be clear and colourless to slightly yellow. Do not use the reconstituted solution if you notice any particles or discolouration. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.

Contents of the pack and other information

What Refixia contains • The active substance is nonacog beta pegol (pegylated human coagulation factor IX (rDNA)). Each vial of Refixia contains nominally 500 IU, 1 000 IU, 2 000 IU or 3 000 IU nonacog beta pegol corresponding to approximately 125 IU/ml, 250 IU/ml, 500 IU/ml or 750 IU/ml respectively after reconstitution with histidine solvent. • The other ingredients in the powder are sodium chloride, histidine, sucrose, polysorbate 80, mannitol, sodium hydroxide and hydrochloric acid. See section 2 "Refixia contains sodium". • The ingredients in the sterilised solvent are histidine, water for injections, sodium hydroxide and hydrochloric acid. What Refixia looks like and contents of the pack • Refixia is provided as a powder and solvent for solution for injection (500 IU, 1 000 IU, 2 000 IU or 3 000 IU powder in a vial and 4 ml solvent in a pre-filled syringe, a plunger rod with a vial adapter – pack size of 1). Not all strengths may be marketed. • The powder is white to off-white and the solvent is clear and colourless. Marketing Authorisation Holder and Manufacturer Novo Nordisk A/S Novo Allé DK-2880 Bagsværd, Denmark This leaflet was last revised in 11/2025

5

Instructions on how to use Refixia Read these instructions carefully before using Refixia. Refixia is supplied as a powder. Before injection a solution must be made up (reconstituted) with the solvent supplied in the syringe. The solvent is a histidine solution. The reconstituted solution must be injected into a vein (intravenous (IV) injection). The equipment in this package is designed to reconstitute and inject Refixia. You will also need an infusion set (tubing and butterfly needle), sterile alcohol swabs, gauze pads and plasters. These items are not included in the Refixia package. Do not use the equipment without proper training from your doctor or nurse. Always wash your hands and ensure that the area around you is clean. When you prepare and inject medicine directly into the veins, it is important to use a clean and germ- free (aseptic) technique. Incorrect technique can introduce germs that can infect the blood. Do not open the equipment until you are ready to use it. Do not use the equipment if it has been dropped, or if it is damaged. Use a new package instead. Do not use the equipment if it has expired. Use a new package instead. The expiry date is printed on the outer carton, on the vial, on the vial adapter, and on the pre-filled syringe. Do not use the equipment if you suspect it is contaminated. Use a new package instead. Do not dispose of any of the items until after you have injected the reconstituted solution. The equipment is for single use only. Contents The package contains: • 1 vial with Refixia powder • 1 vial adapter • 1 pre-filled syringe with solvent • 1 plunger rod (placed under the syringe)

6

Overview Vial with Refixia powder Plastic cap Rubber stopper (under plastic cap)

Vial adapter Protective cap

Spike Protective (under protective paper) paper

Pre-filled syringe with solvent Syringe tip (under syringe cap) Scale

Plunger

Syringe cap

7

Plunger rod Thread

Wide top end

1. Prepare the vial and the syringe •

Take out the number of Refixia packages you need.

•

Check the expiry date.

•

Check the name, strength and colour of the package, to make sure it contains the correct product.

•

Wash your hands and dry them properly using a clean towel or air dry.

•

Take the vial, the vial adapter and the prefilled syringe out of the carton. Leave the plunger rod untouched in the carton.

•

Bring the vial and the pre-filled syringe to room temperature. You can do this by holding them in your hands until they feel as warm as your hands.

•

Do not use any other way to warm the vial and pre-filled syringe.

•

Remove the plastic cap from the vial. If the plastic cap is loose or missing, do not use the vial.

•

Wipe the rubber stopper with a sterile alcohol swab and allow it to air dry for a few seconds before use to ensure that it is as germ free as possible.

•

Do not touch the rubber stopper with your fingers as this can transfer germs.

A

B

8

2. Attach the vial adapter •

C

Remove the protective paper from the vial adapter. If the protective paper is not fully sealed or if it is broken, do not use the vial adapter. Do not take the vial adapter out of the protective cap with your fingers. If you touch the spike on the vial adapter, germs from your fingers can be transferred.

•

Place the vial on a flat and solid surface.

•

Turn over the protective cap, and snap the vial adapter onto the vial.

D

Once attached, do not remove the vial adapter from the vial. •

Lightly squeeze the protective cap with your thumb and index finger as shown.

E

Remove the protective cap from the vial adapter. Do not lift the vial adapter from the vial when removing the protective cap. 3. Attach the plunger rod and the syringe •

Grasp the plunger rod by the wide top end and take it out of the carton. Do not touch the sides or the thread of the plunger rod. If you touch the sides or the thread, germs from your fingers can be transferred.

•

Immediately connect the plunger rod to the syringe by turning it clockwise into the plunger inside the pre-filled syringe until resistance is felt.

F

9

•

Remove the syringe cap from the pre-filled syringe by bending it down until the perforation breaks.

•

Do not touch the syringe tip under the syringe cap. If you touch the syringe tip, germs from your fingers can be transferred.

G

If the syringe cap is loose or missing, do not use the pre-filled syringe. •

Screw the pre-filled syringe securely onto the vial adapter until resistance is felt.

H

4. Reconstitute the powder with the solvent

I

•

Hold the pre-filled syringe slightly tilted with the vial pointing downwards.

•

Push the plunger rod to inject all the solvent into the vial.

•

Keep the plunger rod pressed down and swirl the vial gently until all the powder is dissolved.

J

Do not shake the vial as this will cause foaming. •

Check the reconstituted solution. It must be clear and colourless to slightly yellow and no particles should be visible. If you notice particles or discolouration, do not use it. Use a new package instead.

Refixia is recommended to be used immediately after it has been reconstituted. This is because if left, the medicine may no longer be sterile and could cause infections. If you cannot use the reconstituted Refixia solution immediately, it should be used within 4 hours when stored at room temperature (up to 30 °C) and within 24 hours when stored in a refrigerator (2 °C – 8 °C). Store the reconstituted product in the vial. Do not freeze reconstituted Refixia solution or store it in syringes. Keep reconstituted Refixia solution out of direct light.

10

If your dose requires more than one vial, repeat steps A to J with additional vials, vial adapters and pre-filled syringes until you have reached your required dose. •

Keep the plunger rod pushed completely in.

•

Turn the syringe with the vial upside down.

•

Stop pushing the plunger rod and let it move back on its own while the reconstituted solution fills the syringe.

•

Pull the plunger rod slightly downwards to draw the reconstituted solution into the syringe.

•

In case you only need part of the entire vial, use the scale on the syringe to see how much reconstituted solution you withdraw, as instructed by your doctor or nurse.

K

If, at any point, there is air in the syringe, inject the air back into the vial. •

While holding the vial upside down, tap the syringe gently to let any air bubbles rise to the top.

•

Push the plunger rod slowly until all air bubbles are gone.

•

Unscrew the vial adapter with the vial.

•

Do not touch the syringe tip. If you touch the syringe tip, germs from your fingers can be transferred.

L

5. Inject the reconstituted solution Refixia is now ready to inject into your vein. • Inject the reconstituted solution as instructed by your doctor or nurse. • Inject slowly over 1 to 3 minutes. • Do not mix Refixia with any other intravenous infusions or medicines. Injecting Refixia via needleless connectors for intravenous (IV) catheters Caution: The pre-filled syringe is made of glass and is designed to be compatible with standard luer-lock connections. Some needleless connectors with an internal spike are incompatible with the pre-filled syringe. This incompatibility may prevent administration of the medicine and/or result in damage to the needleless connector.

11

Injecting the solution via a central venous access device (CVAD) such as a central venous catheter or a subcutaneous port: • Use a clean and germ-free (aseptic) technique. Follow the instructions for proper use for your connector and CVAD in consultation with your doctor or nurse. • Injecting into a CVAD may require using a sterile 10 ml plastic syringe for withdrawal of the reconstituted solution. This should be done right after step J. • If the CVAD line needs to be flushed before or after Refixia injection, use sodium chloride 9 mg/ml solution for injection. Disposal •

M

After injection, safely dispose of all unused Refixia solution, the syringe with the infusion set, the vial with the vial adapter and other waste materials as instructed by your pharmacist. Do not throw it out with the ordinary household waste.

Do not disassemble the equipment before disposal. Do not reuse the equipment.

12

Frequently asked questions about Refixia 2000 IU powder and solvent for solution for injection

How do I take Refixia 2000 IU powder and solvent for solution for injection?

Refixia 2000 IU powder and solvent for solution for injection comes as injection containing 2000iu. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Refixia 2000 IU powder and solvent for solution for injection?

The active substance in Refixia 2000 IU powder and solvent for solution for injection is nonacog beta pegol.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Refixia 2000 IU powder and solvent for solution for injection, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Refixia 2000 IU powder and solvent for solution for injection without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Nonacog beta pegol (4 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

Refixia can be used for all age groups.

4.2. Posology and method of administration

Treatment should be under the supervision of a physician experienced in the treatment of haemophilia.

Treatment monitoring

Routine monitoring of factor IX activity levels for the purpose of dose adjustment is not necessary. In the clinical trial programme, dose adjustment was not performed. Mean steady state factor IX trough levels ≥15% were observed for all age groups, see section 5.2 for details.

Due to the interference of polyethylene glycol (PEG) in the one-stage clotting assay with various aPTT reagents, it is recommended to use a chromogenic assay (e.g. Rox Factor IX or Biophen) when monitoring is needed. If a chromogenic assay is not available, it is recommended to use a one-stage clotting assay with an aPTT reagent (e.g. Cephascreen) qualified for use with Refixia. For modified long-acting factor products, it is known that the one-stage clotting assay results are highly dependent on the aPTT reagent and reference standard used. For Refixia, some reagents will cause underestimation (30–50%), while most silica containing reagents will cause severe overestimation of the factor IX activity (more than 400%). Therefore, silica based reagents should be avoided. Use of a reference laboratory is recommended when a chromogenic assay or a qualified one-stage clotting assay is not available locally.

Posology

The number of units of factor IX administered is expressed in International Units (IU), which are related to the current WHO standard for factor IX products. Factor IX activity in plasma is expressed either as a percentage (relative to normal human plasma) or in International Units (relative to an International Standard for factor IX in plasma).

Prophylaxis

40 IU/kg body weight once weekly.

Adjustments of doses and administration intervals may be considered based on achieved FIX levels and individual bleeding tendency. The trough levels achieved with the weekly 40 IU/kg dosing regimen are summarised in section 5.2.

Patients on prophylaxis who forget a dose are advised to take their dose upon discovery and thereafter continue with the usual once weekly dosing schedule. A double dose should be avoided.

On-demand treatment

Dose and duration of the substitution therapy depend on the location and severity of the bleeding, see Table 1 for dosing guidance in bleeding episodes.

Table 1 Treatment of bleeding episodes with Refixia

Degree of haemorrhage

Recommended dose IU/kg of Refixia

Dosing recommendations

Early haemarthrosis, muscle bleeding or oral bleeding.

More extensive haemarthrosis, muscle bleeding or haematoma.

40

A single dose is recommended.

Severe or life threatening haemorrhages.

80

Additional doses of 40 IU/kg can be given.

Surgery

The dose level and dosing intervals for surgery depend on the procedure and local practice. General recommendations are provided in Table 2.

Table 2 Treatment in surgery with Refixia

Type of surgical procedure

Recommended dose IU/kg body weight

Dosing recommendations

Minor surgery including tooth extraction.

40

Additional doses can be given if needed.

Major surgery.

80

Pre-operative dose.

40

Consider two repeated doses of 40 IU/kg (in 1–3 day intervals) within the first week after surgery.

Due to the long half-life of Refixia, the frequency of dosing in the post-surgical period may be extended to once weekly after the first week until bleeding stops and healing is achieved.

Paediatric population

The dose recommendations in children are the same as for adults (for more details on paediatrics see sections 5.1 and 5.2).

Method of administration

Intravenous use.

Refixia is administered by intravenous bolus injection over several minutes after reconstitution of the powder for injection with the histidine solvent. The rate of administration should be determined by the patient's comfort level up to a maximum injection rate of 4 ml/min.

For instructions on reconstitution of the medicinal product before administration, see section 6.6.

In case of self-administration or administration by caregiver appropriate training is needed.

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Known allergic reaction to hamster protein.

4.4. Special warnings and precautions for use

Traceability

In order to improve traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Hypersensitivity

Allergic type hypersensitivity reactions are possible with Refixia. The product contains traces of hamster proteins. If symptoms of hypersensitivity occur, patients should be advised to discontinue use of the medicinal product immediately and contact their physician. Patients should be informed of the early signs of hypersensitivity reactions including hives, generalised urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis.

In case of shock, standard medical treatment for shock should be implemented.

Inhibitors

After repeated treatment with human coagulation factor IX products, patients should be monitored for the development of neutralising antibodies (inhibitors) that should be quantified in Bethesda Units (BU) using appropriate biological testing.

There have been reports in the literature showing a correlation between the occurrence of a factor IX inhibitor and allergic reactions. Therefore, patients experiencing allergic reactions should be evaluated for the presence of an inhibitor. It should be noted that patients with factor IX inhibitors may be at an increased risk of anaphylaxis with subsequent challenge with factor IX.

Because of the risk of allergic reactions with factor IX products, the initial administrations of factor IX should, according to the treating physician's judgement, be performed under medical observation where proper medical care for allergic reactions could be provided.

In case of residual FIX activity levels, there is a risk of interference when performing the Nijmegen modified Bethesda assay for inhibitor testing. Therefore a pre-heating step or a wash-out is recommended in order to ensure detection of low-titre inhibitors.

Thromboembolism

Because of the potential risk of thrombotic complications, clinical surveillance for early signs of thrombotic and consumptive coagulopathy should be initiated with appropriate biological testing when administering this product to patients with liver disease, to patients post-operatively, to new-born infants, or to patients at risk of thrombotic phenomena or DIC. In each of these situations, the benefit of treatment with Refixia should be weighed against the risk of these complications.

Cardiovascular event

In patients with existing cardiovascular risk factors, substitution therapy with FIX may increase the cardiovascular risk.

Catheter-related complications

If a central venous access device (CVAD) is required, risk of CVAD-related complications including local infections, bacteraemia and catheter site thrombosis should be considered.

Paediatric population

The listed warnings and precautions apply both to children and adults.

Sodium content

This medicinal product contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially “sodium-free”. In case of treatment with multiple vials, the total sodium content should be taken into consideration.

4.5. Interaction with other medicinal products and other forms of interaction

No interactions of human coagulation factor IX (rDNA) products with other medicinal products have been reported.

4.6. Fertility, pregnancy and lactation

Animal reproduction studies have not been conducted with factor IX. Based on the rare occurrence of haemophilia B in women, experience regarding the use of factor IX during pregnancy and breastfeeding is not available. Therefore, factor IX should be used during pregnancy and lactation only if clearly indicated.

4.7. Effects on ability to drive and use machines

Refixia has no or negligible influence on the ability to drive and use machines.

4.8. Undesirable effects

Summary of the safety profile

Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) have been observed rarely with recombinant factor IX products and may in some cases progress to severe anaphylaxis (including shock). In some cases, these reactions have progressed to severe anaphylaxis, and they have occurred in close temporal association with development of factor IX inhibitors (see also section 4.4). Nephrotic syndrome has been reported following attempted immune tolerance induction in haemophilia B patients with factor IX inhibitors and a history of allergic reaction.

Very rarely development of antibodies to hamster protein with related hypersensitivity reactions has been observed.

Patients with haemophilia B may develop neutralising antibodies (inhibitors) to factor IX. If such inhibitors occur, the condition will manifest itself as an insufficient clinical response. In such cases, it is recommended that a specialised haemophilia centre is contacted.

There is a potential risk of thromboembolic episodes following the administration of factor IX products, with a higher risk for low purity preparations. The use of low purity factor IX products has been associated with instances of myocardial infarction, disseminated intravascular coagulation, venous thrombosis and pulmonary embolism. The use of high purity factor IX products like Refixia is rarely associated with such adverse reactions.

Tabulated list of adverse reactions

The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level).

Frequencies have been evaluated according to the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

A total of 115 previously treated patients (PTPs) and 54 previously untreated patients (PUPs) with moderate or severe haemophilia B have been exposed to Refixia for a total of 543 patient years in the completed clinical trials.

Table 3 Frequency of adverse reactions in clinical trials

System Organ Class

Adverse reaction

Frequency

Blood and lymphatic system disorders

Factor IX inhibition

Common*

Immune system disorders

Hypersensitivity

Anaphylactic reaction

Common

Common*

Cardiac disorders

Palpitations

Uncommon

Gastrointestinal disorders

Nausea

Common

Skin and subcutaneous tissue disorders

Pruritus**

Rash

Common

Common

General disorders and administration site conditions

Fatigue

Hot flush

Injection site reactions***

Common

Uncommon

Common

* Frequency based on occurrence in PUP trial (N=54)

**Pruritus includes the terms pruritus and ear pruritus

***Injection site reactions include injection site pain, infusion site pain, injection site swelling, injection site erythema and injection site rash.

Description of selected adverse reactions

Factor IX inhibition and anaphylactic reactions have not been observed in PTPs, and frequencies are therefore based on a PUP trial with 54 patients. In this trial, Factor IX inhibition occurred in 4/54 (8%) and anaphylactic reaction occurred in 1/54 (2%) categorising these events as common. The case with anaphylactic reaction occurred in a patient that also developed Factor IX inhibition.

Paediatric population

Frequency, type and severity of adverse reactions in children are expected to be similar as in adults

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Overdoses up to 169 IU/kg have been reported in clinical trials. No symptoms associated with overdoses have been reported.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

  • REFIXIA 1000 UI prescriptionNONACOG BETA PEGOL · injection / infusion
  • REFIXIA 2000 UI prescriptionNONACOG BETA PEGOL · injection / infusion
  • REFIXIA 3000 UI prescriptionNONACOG BETA PEGOL · injection / infusion
  • REFIXIA 500 UI prescriptionNONACOG BETA PEGOL · injection / infusion

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

⚠ Not the same combination. This medicine contains Nonacog beta pegol. The products below do not contain exactly the same set of active substances — they are not direct substitutes.

  • Rixubis partial — not the same combinationNonacogum gamma (rDNA) · injection / infusion

Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Refixia 2000 IU powder and solvent for solution for injection. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →